Investor Relations

A man with his arms crossed


POINT has built a platform to accelerate the next-generation of radiopharmaceuticals with an industry-leading pipeline, in-house manufacturing capabilities, and redundant supply of rare medical isotopes. The management team brings decades of combined experience in radiopharmaceutical clinical development and manufacturing, including 40+ clinical trials, 12 drug approvals, and 8 GMP radiopharmaceutical facilities, and has leveraged prior relationships to assemble one of the industry’s most resilient radioisotope supply chains. The company’s 100%-owned, 80,000 sq ft facility has capacity to commercially supply both North America and Europe for large volume indications. POINT has two late-stage programs one of which is PNT2002, currently being evaluated in the Phase 3 SPLASH study targeting mCRPC, which could lay the cornerstones of the company’s radiopharmaceutical platform. POINT also has an exciting early-stage pipeline which includes a best-in-class FAP-α targeted radioligand PNT2004, a potential pan-cancer target.
Press Release
16 May

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy.

Press Release
13 May

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program; trial is expected to commence this summer.

Events Calendar


May 17: Guggenheim Radiopharmaceuticals Day 2022
- Format: Panel Discussion and Fireside Chat
- Time: 1:30pm ET
- Panel webcast link available here
- Fireside chat available here

May 24: UBS Global Healthcare Conference
- Format: Presentation
- Time: 9:15am ET
- Webcast link available here

June 2: Annual General Meeting

June 3: Institutional Investor Day


February 22: B. Riley Securities’ Radiation Oncology Investor Day
- Format: Fireside Chat
- Time: 11:30 am ET
- Replay
available here

February 25-27:
SNMMI Mid-Winter Meeting
March 7-9: Cowen & Co. 42nd Annual Healthcare Conference
- Format: Panel Discussion
- Panel: GI/GU Oncology Discussion
- Time: 10:30 am ET
- Webcast link available here

March 14: Oppenheimer & Co. “Radiopharmaceutical Therapies Come of Age”
- Format: Fireside Chat
- Time: 1:00 pm ET

March 15-17: Oppenheimer & Co. 32nd Annual Healthcare Conference 
- Format: Virtual Presentation
- Time: 2:00 pm ET
- Webcast link available here

March 25: Q4 2021 Results 

March 29: "Introduction to Dosimetry for Radiopharmaceuticals"
- Format: POINT Webinar
- Replay available here

April 8-13: American Association for Cancer Research (AACR) Annual Meeting 

April 28: Proxy Filing

May 2: Bloom Burton Healthcare Investor Conference
- Format: Presentation
- Time: 4:00pm ET
- Webcast link available here

May 13: Q1 2022 Results 

December 6: "The First Principles of Radiopharmaceuticals"
- Format: POINT Webinar
- Replay
available here

Stock, Financials & Governance

Financial Reports
Board of Directors
Stock Price
SEC Filings
Section 16 Filings

Governance Documents
Audit Committee Charter
Code of Business Conduct and Ethics
Whistleblower Line Information
Compensation Committee Charter
Corporate Governance Guidelines
Nominating and Corporate Governance Committee Charter

Analyst Coverage
Brookline - Kemp Dolliver
Cowen - Boris Peaker
Jefferies - Chris Howerton
Piper Sandler - Ted Tenthoff
Please note, this list of analyst coverage may not complete or up to date. Any opinions, estimates or forecasts regarding performance made by analysts do not represent POINT Biopharma or its management team.



1-833-544-2637 x800

Please do not submit any private or confidential information using this form. Fields marked with an asterisk (*) are required.

Thank you!
Your submission has been received!
Oops! Something went wrong while submitting the form.